Northwest Biotherapeutics Inc (NASDAQ:NWBO) a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that ASCO (the American Society for Clinical Oncology) has announced in its Annual Meeting program that the Company will present its DCVax-Direct clinical trial and technology in a general poster session at this year’s ASCO meeting, taking place in Chicago May 30 through June 3. The abstract is number TPS3133, and the poster is number 189(a). Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares after opening at $5.82 moved to $5.88 on last trade day and at the end of the day closed at $5.52 . Company price to sales ratio in past twelve months was calculated as 386.47 and price to cash ratio as 16.71. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) showed a negative weekly performance of -6.44%.
CytRx Corporation (NASDAQ:CYTR) a biopharmaceutical research and development company specializing in oncology, presented updated progression-free survival (PFS) and overall survival (OS) results from its completed Phase 1b/2 clinical trial of aldoxorubicin in patients with advanced soft tissue sarcoma (STS). The data were presented as part of CytRx’s Research and Development Day which took place Friday, May 2, 2014 at the Harvard Club in New York City. CytRx Corporation (NASDAQ:CYTR) shares fell -5.34% in last trading session and ended the day on $3.19. CYTR return on equity ratio is recorded as -287.90% and its return on assets is -146.40%. CytRx Corporation (NASDAQ:CYTR) yearly performance is 20.83%.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) a biopharmaceutical company focused on developing breakthrough treatments for human disease, will release its first quarter 2014 financial results on Thursday, May 8, 2014 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the first quarter 2014 at 11:00 a.m. Eastern Time on May 8, 2014. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares moved down -6.00% in last trading session and was closed at $1.41 while trading in range of $ 1.40 – $1.51. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) year to date (YTD) performance is -21.67%.
XOMA Corporation (NASDAQ:XOMA) a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, 2014, at 4:30 p.m. Eastern time to discuss first quarter 2014 financial results and provide an update on gevokizumab’s global clinical programs. XOMA Corp (NASDAQ:XOMA) weekly performance is -23.87%. On last trading day company shares ended up $4.29. XOMA Corp (NASDAQ:XOMA) distance from 50-day simple moving average (SMA50) is -6.54%. Analysts mean target price for the company is $9.25.